Description

Asibrox (Acetylcysteine) Effervescent Tablets 600 mg. №10

Ingredients

Each effervescent tablet contains 600 mg of acetylcysteine as the active ingredient.

Mechanism of Action

Acetylcysteine, the active ingredient in Asibrox tablets, is a mucolytic agent that works by breaking down mucus in the respiratory tract, making it easier to clear the airways.

Pharmacological Properties

Studies have shown that acetylcysteine can help reduce the viscosity of mucus, improve lung function, and decrease the frequency of exacerbations in patients with chronic bronchitis and COPD.

Indications for Use

Asibrox effervescent tablets are indicated for the treatment of respiratory conditions such as bronchitis, pneumonia, and chronic obstructive pulmonary disease (COPD).

Contraindications

Do not use Asibrox tablets if you are allergic to acetylcysteine or any other ingredients in the product.

Side Effects

No common side effects have been reported with the use of Asibrox tablets. However, if you experience any unusual symptoms, discontinue use and consult a healthcare professional.

Usage Instructions

The recommended dosage for adults is one effervescent tablet daily, dissolved in a glass of water. Do not chew the tablet.

Benefits Compared to Analogues

Asibrox tablets offer the advantage of convenient once-daily dosing and proven efficacy in reducing exacerbations and improving quality of life in patients with COPD compared to similar products.

Suitable Patient Groups

Asibrox tablets are suitable for adults including the elderly population. Consult a healthcare provider for appropriate use in children.

Storage and Shelf Life

• Storage: Store in a cool, dry place away from direct sunlight.
• Shelf Life: Check the expiration date on the packaging and do not use the product after that date.

Packaging Description

Asibrox effervescent tablets are packaged in blister packs containing 10 tablets per pack. The packaging is designed to maintain the stability and integrity of the tablets.

Clinical Evidence and Proven Effectiveness

Research published in the International Journal of Chronic Obstructive Pulmonary Disease demonstrated that acetylcysteine therapy was associated with a significant reduction in the number of acute exacerbations and improved quality of life in COPD patients.